MarketPulse
I

$IBRX

63 articles found
9 positive
52 negative
1 neutral
The Motley FoolThe Motley Fool··Josh Kohn-Lindquist

ImmunityBio Gains 41% Following European Approval of Bladder Cancer Therapy

ImmunityBio shares surged 41% after Europe approved its bladder cancer therapy ANKTIVA, enabling commercialization across 30+ nations and opening significant revenue opportunities.
IBRXIOVAKRYSbiotechbladder cancer
BenzingaBenzinga··Prnewswire

Biotech Pipeline Expands Arsenal Against Treatment-Resistant Cancers

Biotech firms advance treatment-resistant cancer therapies across multiple platforms, including oncolytic viruses and cellular immunotherapy, with several candidates achieving regulatory milestones and encouraging clinical data.
IBRXONCYNVCRCATXNUVBcolorectal cancerFDA approval
BenzingaBenzinga··Erica Kollmann

Short Interest Surges in Hospitality and EV Stocks Amid Market Skepticism

Short interest surges in hospitality and EV stocks as investors bet against overvalued companies. Choice Hotels, Lucid, and Avis lead with over 48% short positions.
IBRXHIMSCHHLCIDCAR+2market volatilityshort squeeze